(Sanofi) Sanofi SA plans to invest 400 million euros or $477 million in a year to build an mRNA vaccine business.
Sanofi expects the investment in mRNA research to generate at least six candidate vaccines by 2025.
The investment allows Sanofi to become the latest drugmaker to embrace mRNA to produce new vaccines faster.
The drugmaker ventured into mRNA vaccine research in 2018 in collaboration with Translate Bio and, last year, expanded the partnership to include a Covid-19 shot already in clinical trials.
mRNA is reshaping the vaccine industry and is now the leading source of Covid-19 shots, despite not producing an approved product before the pandemic.
SNY: NASDAQ is up down -0.29% on premarket.
